Literature DB >> 11228387

Identification of substrains of BCG vaccine using multiplex PCR.

J Bedwell1, S K Kairo, M A Behr, J A Bygraves.   

Abstract

Current methods for determining the identity of substrains of Mycobacterium bovis BCG (BCG) vaccine are labour intensive, or provide only limited substrain differentiation. In this paper we describe a multiplex PCR that distinguishes between M. tuberculosis (TB) and M. bovis and the non-pathogenic BCG strain, and also subdivides the BCG vaccine substrains investigated into seven distinct fingerprints based on six target regions in the DNA. This test is specific, rapid, reproducible and portable and is proposed as a novel test for BCG vaccine control. It offers substantial advantages over the methods currently in use. Using this test we have characterised a number of commercial BCG vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228387     DOI: 10.1016/s0264-410x(00)00369-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro.

Authors:  Ana M Aguirre-Blanco; Pauline T Lukey; Jacqueline M Cliff; Hazel M Dockrell
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

Review 2.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

3.  Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain.

Authors:  Takashi Naka; Shinji Maeda; Mamiko Niki; Naoya Ohara; Saburo Yamamoto; Ikuya Yano; Jun-Ichi Maeyama; Hisashi Ogura; Kazuo Kobayashi; Nagatoshi Fujiwara
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

4.  Improvement of differentiation and interpretability of spoligotyping for Mycobacterium tuberculosis complex isolates by introduction of new spacer oligonucleotides.

Authors:  A G M van der Zanden; K Kremer; L M Schouls; K Caimi; A Cataldi; A Hulleman; N J D Nagelkerke; D van Soolingen
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

5.  Multiplex PCR-identified cutaneous tuberculosis evoked by Mycobacterium bovis BCG vaccination in a healthy baby.

Authors:  Tatsuma Okazaki; Satoru Ebihara; Hidenori Takahashi; Masanori Asada; Akimasa Sato; Masaaki Seki; Hideyasu Ohto; Hidetada Sasaki
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Joint effects of host genetic background and mycobacterial pathogen on susceptibility to infection.

Authors:  Tania Di Pietrantonio; José A Correa; Marianna Orlova; Marcel A Behr; Erwin Schurr
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

7.  Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model.

Authors:  S M Irwin; A Goodyear; A Keyser; R Christensen; J M Troudt; J L Taylor; A Bohsali; V Briken; A A Izzo
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

8.  Mediastinal mass mimicking a tumor in a patient with bladder cancer after Bacillus Calmette-Guerin treatment.

Authors:  A Somoskovi; C Carlyn; J Dormandy; M Salfinger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

9.  Tokyo-172 BCG vaccination complications, Taiwan.

Authors:  Ruwen Jou; Wei Lun Huang; Wei Ju Su
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

10.  Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.

Authors:  Narcís Saubi; Alice Mbewe-Mvula; Ester Gea-Mallorqui; Maximillian Rosario; Josep Maria Gatell; Tomáš Hanke; Joan Joseph
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.